Treatment of prostate cancer in unfit senior adult patients

Cancer Treatment Reviews

Volumn 35, Issue 6, 2009, Pages 522-527

  Falci, Cristina ^a   Morello, Elisabetta ^b   Droz, Jean Pierre ^c  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Chemotherapy; Elderly; Geriatric assessment; Hormonal therapy; Prostate cancer; Radiotherapy; Unfit

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYANOCOBALAMIN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUTICASONE; GABAPENTIN; GONADORELIN; GONADORELIN DERIVATIVE; GOSERELIN; IRON; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; VENLAFAXINE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANEMIA; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE FREE SURVIVAL; ERECTILE DYSFUNCTION; FLUSHING; FUNCTIONAL STATUS; GERIATRIC DISORDER; GYNECOMASTIA; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MASTALGIA; MUSCLE ATROPHY; NAUSEA AND VOMITING; OSTEOPOROSIS; OVERALL SURVIVAL; PAIN; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE PLANNING; PRACTICE GUIDELINE; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REHABILITATION CARE; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SURVIVAL TIME; SYMPTOM; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; VASOMOTOR DISORDER;

AGED; ANDROGEN ANTAGONISTS; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 70349319631     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.04.014     Document Type: Review

References (44)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Ries L. SEER Cancer Statistics Review, 1975-2003; 44: 637-649 (SEER web site, 2006).
3. Balducci L., and Yates J. General guidelines for the management of older patients with cancer. Oncology 14 11A (2000) 221-227
4. Basso L, Vamvakas C, Falci E, Lamberti LM, Pasetto A, Brunello S, et al. Management and survival of frail elderly cancer patients within a Geriatric Oncology Program. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24 No 18S (June 20 Suppl.), 2006: 8547.
5. Terret C., Albrand G., and Droz J.P. Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2 4 (2004) 236-240 [Crit Rev Oncol Hematol 2005;55(3):241-52]
6. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
7. Mohile S.G., Bylow K., Dale W., et al. A pilot study of the Vulnerable Elders Survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109 (2007) 802-810
8. Droz J.P., Balducci L., Bolla M., et al. SIOG prostate cancer guidelines proposals in senior adult men. Crit Rev Oncol Hematol 60 S9 (2006) [abstr. IVA]
9. Newschaffer C.J., Otani K., McDonald M.K., and Penberthy L.T. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92 8 (2000) 613-621
10. Walter L.C., and Covinsky K.E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 285 21 (2001) 2750-2756
11. D'Amico A.V., Moul J., Carroll P., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol 11 (2003) 2163-2172
12. Heidenreich A., Aus G., Bolla M., et al. European association of urology guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
13. Alibhai S.M.H., Leach M., Tomlinson G., et al. 30-days mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst (2005) 1525-1532
14. Logothetis C.J., Hoosein N.M., and Hsieh J.T. The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol 21 5 (1994) 620-629
15. Antonarakis E.S., and Eisenberger M.A. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?. Nat Clin Pract Urol 5 9 (2008) 480-481
16. Kirk D. Prostate cancer in elderly. Eur J Surg Oncol 24 (1998) 379-383
17. Studer U.E., Whelan P., Albrecht W., Casselman J., de Reijke T., Hauri D., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 12 (2006) 1868-1876
18. Green H.J., Pakenham K.I., Headley B.C., et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int (2004) 975-979
19. Joly F., Alibhai S.M., Galica J., Park A., Yi Q.L., Wagner L., et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 176 6 Pt 1 (2006) 2443-2447
20. Higano C.S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61 (2003) 32-38
21. Adelson K.B., Loprinzi C.L., and Hershman D.L. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother 6 (2005) 1095-1106
22. Diamond T.H., Higano C.S., Smith M.R., Guise T.A., and Singer F.R. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Recommendations for diagnosis and therapies. Cancer 100 (2004) 892-899
23. Shahinian V.B., Kuo Y.F., Ensrud K.E., et al. Risk of fractures after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
24. Saad, F., Sternberg, C.N. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nat Clin Pract Urol, 4, S3-13.
25. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 9 (2007) 1038-1042
26. Smith M.R. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol 170 6 Pt 2 (2003) S55-S57
27. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., and Aapro M. International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 43 (2007) 852-858
28. Thompson C.A., Shanafelt T.D., Loprinzi L., and Andropause. Symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8 (2003) 474-487
29. Strum S.B., McDermed J.E., Scholz M.C., Johnson H., and Tisman G. Anemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 (1997) 933-941
30. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
31. Green H.J., Pakenham K.I., Headley B.C., et al. Altered cognitive function in men treated for prostate cancer with luteining hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 (2002) 427-433
32. Bylow K., Mohile S.G., Stadler W.M., and Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?. Cancer 15 (2007) 2604-2613
33. Droz J.P., and Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int 101 Suppl. 2 (2008) 23-29
34. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
35. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 7 (2004) 1513-1520
36. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
37. Beer T.M., Berry W., Wersinger E.M., and Bland L.B. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2 (2003) 167-172
38. Fossa S.D., Jacobsen A.B., Ginman C., Jacobsen I.N., Overn S., Iversen J.R., et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 52 6 (2007) 1691-1698 [Epub 2007 Feb 8]
39. Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2008 [Epub ahead of print].
40. Ohlmann C.H., Engelmann U.H., and Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPC) previously treated with docetaxel-based chemotherapy. J Clin Oncol 23 (2005) [abstr. 4682]
41. Bianco F.J., Scardino P.T., and Eastham J.A. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("Trifecta"). Urology 66 Suppl. 5 (2005) 83-94
42. Hunter KF, Glazener CM, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2007, Issue 2 [Review].
43. Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: what do we know?. Crit Rev Oncol Hematol 57 2 (2006) 165-173
44. Franklin D.J., and Packel L. Cancer-related fatigue. Cardiopulmonary rehabilitation and cancer rehabilitation: focused review. Arch Phys Med Rehabil 87 3 Suppl. 1 (2006) S91-S93